The percentage of GFP‐positive leukaemia cells also reduced significantly in the bone marrow, liver, and spleen of the mice treated with CD33‐targeting RBCEVs loaded with FLT3‐ITD ASO as compared to the control groups (Figure 5G). The gene discussed is FLT3; the disease is leukemia.